Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.46 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.41 |
| ▸ | FABP4 | P15090 | 1/20 | 0.40 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.40 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | P2RX4 | Q99571 | 3/20 | 0.39 |
| ▸ | HSD17B3 | P37058 | 1/20 | 0.39 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.38 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20139342 | 1.00 | KDM4E (0.47) | KDM4EMAPTMEN1POLBKMT2A | |
| SCHEMBL27090004 | 0.96 | HDAC3 (0.46) | KDM4EMAPTMEN1POLBKMT2A | |
| SCHEMBL23883100 | 0.95 | HDAC3 (0.48) | KDM4EMAPTMEN1POLBKMT2A | |
| SCHEMBL23883102 | 0.95 | HDAC3 (0.48) | KDM4EMAPTMEN1POLBKMT2A | |
| SCHEMBL25697533 | 0.81 | HDAC3 (0.51) | HDAC3P2RX4HSD17B3LMNAMTNR1A | |
| SCHEMBL23950142 | 0.80 | HDAC3 (0.35) | KDM4EMAPTMEN1POLBKMT2A | |
| SCHEMBL19432848 | 0.80 | NOTUM (0.48) | KDM4EMAPTMEN1POLBKMT2A | |
| SCHEMBL18730195 | 0.80 | MAPT (0.50) | KDM4EMAPTMEN1POLBKMT2A | |
| SCHEMBL25698882 | 0.78 | HDAC3 (0.45) | KDM4EMAPTMEN1POLBKMT2A | |
| SCHEMBL27271336 | 0.76 | ALDH1A1 (0.47) | KDM4EMAPTMEN1KMT2ATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12605459-B2 | Protein-drug conjugates comprising camptothecin analogs and methods of use thereof | REGENERON PHARMACEUTICALS, INC. (US) | 2026-04-21 | — | — | US | disclosed |
| US-12497460-B2 | Anti-MSR1 antibodies and methods of use thereof | REGENERON PHARMACEUTICALS, INC. (US) | 2025-12-16 | — | — | US | disclosed |
| EP-4659809-A2 | STEROIDS AND PROTEIN-CONJUGATES THEREOF | Regeneron Pharmaceuticals, Inc. (US) | 2025-12-10 | — | — | EP | disclosed |
| US-12419963-B2 | Diels-Alder conjugation methods | REGENERON PHARMACEUTICALS, INC. (US) | 2025-09-23 | — | — | US | disclosed |
| EP-3538539-B1 | STEROIDS AND PROTEIN-CONJUGATES THEREOF | REGENERON PHARMA (US) | 2025-08-27 | — | — | EP | disclosed |
| US-12377159-B2 | Steroids and protein-conjugates thereof | REGENERON PHARMACEUTICALS, INC. (US) | 2025-08-05 | — | — | US | disclosed |
| US-20250171622-A1 | BIS-OCTAHYDROPHENANTHRENE CARBOXAMIDE DERIVATIVES AND PROTEIN CONJUGATES THEREOF FOR USE AS LXR AGONISTS | REGENERON PHARMACEUTICALS, INC. | 2025-05-29 | — | — | US | disclosed |
| US-20250064954-A1 | STEROIDS AND ANTIBODY-CONJUGATES THEREOF | REGENERON PHARMACEUTICALS, INC. | 2025-02-27 | — | — | US | disclosed |
| US-12209180-B2 | Bis-octahydrophenanthrene carboxamide derivatives and protein conjugates thereof for use as LXR agonists | REGENERON PHARMACEUTICALS, INC. (US) | 2025-01-28 | — | — | US | disclosed |
| US-20240408223-A1 | HYDROPHILIC LINKERS FOR ANTIBODY DRUG CONJUGATES | REGENERON PHARMA (US) | 2024-12-12 | — | — | US | disclosed |
| US-20220080052-A1 | BIS-OCTAHYDROPHENANTHRENE CARBOXAMIDE DERIVATIVES AND PROTEIN CONJUGATES THEREOF FOR USE AS LXR AGONISTS | REGENERON PHARMACEUTICALS, INC. | 2022-03-17 | — | — | US | disclosed |
| US-20220072141-A1 | PROTEIN-DRUG CONJUGATES COMPRISING CAMPTOTHECIN ANALOGS AND METHODS OF USE THEREOF | REGENERON PHARMACEUTICALS, INC. (US) | 2022-03-10 | — | — | US | disclosed |
| US-20210332080-A1 | HYDROPHILIC LINKERS FOR ANTIBODY DRUG CONJUGATES | REGENERON PHARMACEUTICALS, INC. | 2021-10-28 | — | — | US | disclosed |
| US-20210040144-A1 | STEROIDS AND PROTEIN-CONJUGATES THEREOF | REGENERON PHARMACEUTICALS, INC. | 2021-02-11 | — | — | US | disclosed |
| US-10711032-B2 | Steroids and protein-conjugates thereof | REGENERON PHARMACEUTICALS, INC. (US) | 2020-07-14 | — | — | US | disclosed |
| EP-3538539-A2 | STEROIDS AND PROTEIN-CONJUGATES THEREOF | Regeneron Pharmaceuticals, Inc. (US) | 2019-09-18 | — | — | EP | disclosed |
| US-20190070306-A1 | OPTIMIZED TRANSGLUTAMINASE SITE-SPECIFIC ANTIBODY CONJUGATION | REGENERON PHARMACEUTICALS, INC. | 2019-03-07 | — | — | US | disclosed |
| WO-2018089373-A9 | STEROIDS AND PROTEIN-CONJUGATES THEREOF | REGENERON PHARMACEUTICALS, INC. (US) | 2018-07-12 | — | — | WO | disclosed |
| US-20180155389-A1 | STEROIDS AND PROTEIN-CONJUGATES THEREOF | REGENERON PHARMACEUTICALS, INC. | 2018-06-07 | — | — | US | disclosed |
| WO-2018089373-A2 | STEROIDS AND PROTEIN-CONJUGATES THEREOF | REGENERON PHARMACEUTICALS, INC. (US) | 2018-05-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (15 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12209180-B2 | Bis-octahydrophenanthrene carboxamide derivatives and protein conjugates thereof for use as LXR agonists | NR1H3, NR1H2, NR1H4 | KDM4E 1813/4885MAPT 1514/4885MEN1 4636/4885 |
| US-20210332080-A1 | HYDROPHILIC LINKERS FOR ANTIBODY DRUG CONJUGATES | CD44, CD47, EPCAM | KDM4E 1881/4885MAPT 627/4885MEN1 3862/4885 |
| US-20220072141-A1 | PROTEIN-DRUG CONJUGATES COMPRISING CAMPTOTHECIN ANALOGS AND METHODS OF USE THEREOF | TGM2, QPCT, TGM3 | KDM4E 1645/4885MAPT 2636/4885MEN1 847/4885 |
| US-12605459-B2 | Protein-drug conjugates comprising camptothecin analogs and methods of use thereof | FOLH1, TGM2, SLC3A2 | KDM4E 1900/4885MAPT 1133/4885MEN1 560/4885 |
| US-20180155389-A1 | STEROIDS AND PROTEIN-CONJUGATES THEREOF | SERPINA6, NR3C1, NR3C2 | KDM4E 4467/4885MAPT 3285/4885MEN1 2876/4885 |
| US-20250064954-A1 | STEROIDS AND ANTIBODY-CONJUGATES THEREOF | SERPINA6, NR3C1, NR3C2 | KDM4E 4292/4885MAPT 2910/4885MEN1 2331/4885 |
| US-20250171622-A1 | BIS-OCTAHYDROPHENANTHRENE CARBOXAMIDE DERIVATIVES AND PROTEIN CONJUGATES THEREOF FOR USE AS LXR AGONISTS | NR1H3, NR1H2, NR1H4 | KDM4E 1813/4885MAPT 1514/4885MEN1 4636/4885 |
| US-12497460-B2 | Anti-MSR1 antibodies and methods of use thereof | CD47, MSR1, LDLR | KDM4E 1108/4885MAPT 4571/4885MEN1 1417/4885 |
| US-10711032-B2 | Steroids and protein-conjugates thereof | SERPINA6, NR3C1, NR3C2 | KDM4E 4467/4885MAPT 3285/4885MEN1 2876/4885 |
| US-20210040144-A1 | STEROIDS AND PROTEIN-CONJUGATES THEREOF | SERPINA6, NR3C1, NR3C2 | KDM4E 4484/4885MAPT 2999/4885MEN1 2791/4885 |
| US-20190070306-A1 | OPTIMIZED TRANSGLUTAMINASE SITE-SPECIFIC ANTIBODY CONJUGATION | TGM2, TGM3, TGM1 | KDM4E 1627/4885MAPT 1825/4885MEN1 2353/4885 |
| US-12377159-B2 | Steroids and protein-conjugates thereof | SERPINA6, NR3C1, NR3C2 | KDM4E 4484/4885MAPT 2999/4885MEN1 2791/4885 |
| US-20220080052-A1 | BIS-OCTAHYDROPHENANTHRENE CARBOXAMIDE DERIVATIVES AND PROTEIN CONJUGATES THEREOF FOR USE AS LXR AGONISTS | NR1H3, NR1H2, NR1H4 | KDM4E 1813/4885MAPT 1514/4885MEN1 4636/4885 |
| US-20240408223-A1 | HYDROPHILIC LINKERS FOR ANTIBODY DRUG CONJUGATES | CD44, CD47, EPCAM | KDM4E 1881/4885MAPT 627/4885MEN1 3862/4885 |
| US-12419963-B2 | Diels-Alder conjugation methods | GLUL, TGM2, GLS | KDM4E 1011/4885MAPT 796/4885MEN1 613/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.